Iizuka T, Kakegawa T, Ida H, Ando N, Watanabe H, Takagi I
Department of Surgery, National Oji Hospital, Tokyo.
Jpn J Clin Oncol. 1991 Jun;21(3):176-9.
In the present phase II study, 31 patients with advanced measurable esophageal carcinomas were treated with a combination of 30 mg vindesine/m2 and 70 mg cisplatin/m2. The overall response rate was 16.1% (95% confidence limits, 7.1-32.6%). Responses were seen in metastatic sites, including the liver in two patients, a lung in one, neck or mediastinal lymph nodes in two and primary sites in two. The response durations were between one and two months for patients achieving partial response. The average survival time after first administration was 5.5 months for patients who responded to treatment, whereas, for those who did not, it was 7.3 months. The major form of toxicity was myelosuppression, 14 patients developed grade 2-3 toxicity and one sepsis which led to death. No superiority of the combined chemotherapy over either cisplatin or vindesine therapy alone was suggested for cases of advanced squamous cell carcinoma of the esophagus by the present study.
在目前的II期研究中，31例晚期可测量食管癌患者接受了30mg长春地辛/m²和70mg顺铂/m²的联合治疗。总缓解率为16.1%（95%置信区间，7.1 - 32.6%）。在转移部位出现缓解，包括2例患者的肝脏、1例患者的肺部、2例患者的颈部或纵隔淋巴结以及2例患者的原发部位。达到部分缓解的患者缓解持续时间为1至2个月。对治疗有反应的患者首次给药后的平均生存时间为5.5个月，而无反应的患者为7.3个月。主要毒性形式为骨髓抑制，14例患者出现2 - 3级毒性，1例败血症导致死亡。本研究未表明联合化疗对于晚期食管鳞状细胞癌病例优于单独使用顺铂或长春地辛治疗。
